Objectives To compare the prevalence, regulations, and pharmacovigilance practices of
clozapine use in Eastern European countries (except Russia). Methods Questionnaires and …

Schizophrenia is a debilitating psychiatric disorder that is treated with antipsychotics.
However, despite their efficacy, antipsychotics increase the risk of metabolic disorders in a …

Schizophrenia (SCZ) is a serious mental illness that affects 1% of people worldwide. SCZ is
associated with a higher risk of developing metabolic disorders such as obesity …

Introduction People with severe mental illness have poor cardiometabolic health. Commonly
used antidepressants and antipsychotics frequently lead to weight gain, which may further …

Objective Quetiapine use at standard doses has been associated with hyperglycemia and
dyslipidemia. However, whether even frequently prescribed low‐dose quetiapine results in …

Antipsychotic (AP) medications, such as olanzapine (OLZ), are used in the treatment of
schizophrenia and a growing number of 'off‐label'conditions. A single dose of OLZ causes …

Olanzapine is one of the most effective medicines available for stabilizing schizophrenia
spectrum disorders. However, it has been reported to show the greatest propensity for …

Psychotropic drugs may be associated with metabolic disorders, often but not only triggered
by weight gain. Disorders include dysglycemia and diabetes, atherogenic dyslipidemia and …

Abstract Purpose of Review Weight gain is a disconcerting issue experienced by patients
treated with antipsychotics (APs). This review summarizes current knowledge on the …

The challenges of drug development in pediatric, pregnant and geriatric populations are a
worldwide concern shared by regulatory authorities, pharmaceutical companies, and …